Welcome to our dedicated page for Alopexx news (Ticker: ALPX), a resource for investors and traders seeking the latest updates and insights on Alopexx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alopexx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alopexx's position in the market.
Alpex Acquisition (Nasdaq: ALPX), a blank check company, announced that starting July 7, 2026, holders of its 11,500,000 units from the IPO may separately trade the Class A ordinary shares, warrants and rights.
Units will trade as ALPXU, shares as ALPX, warrants as ALPXW and rights as ALPXR.
Alpex Acquisition Corporation (NASDAQ: ALPXU) closed its $115,000,000 initial public offering of 11,500,000 units at $10.00 per unit, including full over-allotment exercise. Units began trading on Nasdaq on June 25, 2026.
Each unit includes one Class A share, one redeemable warrant, and one right. A concurrent private placement of 187,500 units raised $1,875,000. $115,000,000 of net proceeds was placed in a trust account.
Alpex Acquisition Corporation (NASDAQ: ALPXU) priced its $100 million IPO, offering 10,000,000 units at $10.00 per unit. The units begin trading on Nasdaq on June 25, 2026 under ALPXU, with closing expected June 26, 2026, subject to customary conditions.
Each unit includes one Class A ordinary share, one redeemable warrant exercisable at $11.50, and one right to receive one-fourth of one Class A share upon a business combination. Underwriters hold a 45-day option to buy up to 1,500,000 additional units for over-allotments.